Gossamer Bio, Inc. (FRA:4GB)
Germany · Delayed Price · Currency is EUR 2.724
-0.082 (-2.92%)
At close: Dec 1, 2025
Gossamer Bio Company Description
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States.
The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.
It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds.
The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017.
The company was incorporated in 2015 and is headquartered in San Diego, California.
Gossamer Bio, Inc.
| Country | United States |
| Founded | 2015 |
| Industry | Biological Products, Except Diagnostic Substances |
| Employees | 145 |
| CEO | Faheem Hasnain |
Contact Details
Address: 3115 Merryfield Row San Diego, Delaware 92121 United States | |
| Phone | 858 684 1300 |
| Website | gossamerbio.com |
Stock Details
| Ticker Symbol | 4GB |
| Exchange | Frankfurt Stock Exchange |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Faheem Hasnain | Chief Executive Officer |
| Bryan Giraudo | Chief Financial Officer |
| Bryan Giraudo | Chief Operating Officer |